Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan;22(1):6-11.
doi: 10.1038/cdd.2014.87. Epub 2014 Jun 27.

Role of miR-15/16 in CLL

Y Pekarsky  1 , C M Croce  1
Affiliations
Review

Role of miR-15/16 in CLL

Y Pekarsky et al. Cell Death Differ. 2015 Jan.

Abstract

B-cell chronic lymphocytic leukemia (CLL) is the most common adult leukemia. The most common chromosomal abnormalities detectable by cytogenetics include deletion at 13q (55%), 11q (18%), trisomy 12 (12-16%) and 17p (8%). In 2002, we discovered that a microRNA cluster miR-15a/miR-16-1 (miR-15/16) is the target of 13q deletions in CLL. MicroRNAs encoded by the miR-15/16 locus (miR-15 and miR-16) function as tumor suppressors. Expression of these miRNAs downregulated in CLL, melanoma, colorectal cancer, bladder cancer and other solid tumors. miR-15/16 cluster targets multiple oncogenes, including BCL2, Cyclin D1, MCL1 and others. The most important target of miR-15/16 in CLL is arguably BCL2, as BCL2 is overexpressed in almost all CLLs. In this review, we discuss the discovery, functions, clinical relevance and treatment opportunities related to miR-15/16.

PubMed Disclaimer

Figures

Figure 1
Figure 1
13q14 genomic region deleted in CLL
Figure 2
Figure 2
TP53–miR-15/16 circuitry in CLL
Figure 3
Figure 3
DLEU7 inhibits NF-kB activation in CLL
Figure 4
Figure 4
DLEU7 and miR-15/16 are two cooperating tumor suppressors at 13q14
See this image and copyright information in PMC

References

    1. Sgambati M, Linet M, Devesa S.Chronic Lymphocytic Leukemia, Epidemiological, Familial, and Genetic Aspects. Chronic Lymphocytic Leukemias, Revised and Expanded, 2nd ednIn: Cheson B, (ed).Marcel Dekker, Inc: New York, NY, USA; 200133–62.
    1. Bullrich F, Croce C.Molecular Biology of Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemias, Revised and Expanded, 2nd ednIn: Cheson B, (ed). Marcel Dekker, Inc: New York, NY, USA; 20019–32.
    1. Edelmann J, Holzmann K, Miller F, Winkler D, Buhler A, Zenz T, et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood. 2012;120:4783–4794. - PubMed
    1. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–1916. - PubMed
    1. Stilgenbauer S, Nickolenko J, Wilhelm J, Wolf S, Weitz S, Dohner K, et al. Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Oncogene. 1998;16:1891–1897. - PubMed

MeSH terms